New drug cocktail targets Hard-to-Treat stomach cancer

NCT ID NCT07102901

Recruiting now Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This Phase 2 trial is testing whether a new targeted drug called SHR2554, taken as a tablet, can be safely combined with other anti-cancer injections to treat advanced stomach or gastroesophageal junction cancer. The study will enroll 351 adults whose cancer has spread or cannot be removed by surgery. Researchers will monitor side effects and measure how well the tumors shrink or stop growing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR2554 tablets (a targeted cancer drug) combined with other anti-tumor injections (SHR-A1811, SHR-A1904, SHR-1701)
What this could lead to: If successful, this could provide a new treatment option for people with advanced gastric cancer that has stopped responding to standard therapies.
What could go wrong: This is an early Phase 2 trial, so the combination may not work better than existing treatments. Side effects from the drug combinations could be serious or hard to manage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric carcinoma gastric neoplasm gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED GASTRIC CANCER GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA METASTATIC GASTRIC CANCER

Contacts and locations

Locations

Harbin Medical University Cancer Hospital
RECRUITING

Harbin, Heilongjiang, 150081, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, 450052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.